Share Price and Basic Stock Data
Last Updated: February 9, 2026, 10:08 pm
| PEG Ratio | -6.86 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Concord Drugs Ltd operates in the pharmaceuticals sector, with its stock price currently standing at ₹77.0 and a market capitalization of ₹77.0 Cr. The company’s revenue trends reveal a fluctuating sales pattern over recent quarters. For instance, sales recorded ₹13.72 Cr in September 2022, followed by a slight decline to ₹13.53 Cr in December 2022. A more significant drop occurred in the subsequent quarters, with sales reaching a low of ₹7.38 Cr in September 2023 before rebounding to ₹12.62 Cr in December 2023. The trailing twelve months (TTM) sales amounted to ₹42.18 Cr, reflecting a decrease compared to the ₹51.31 Cr recorded in the fiscal year ending March 2023. This downward trend underscores challenges faced by the company in maintaining consistent revenue growth, which contrasts with the industry’s growth expectations.
Profitability and Efficiency Metrics
Concord Drugs Ltd’s profitability metrics have shown variability, with a reported net profit of ₹0.53 Cr for September 2023, a slight improvement from ₹0.49 Cr in June 2023. However, the company’s operating profit margin (OPM) fluctuated significantly, peaking at 20.73% in September 2023 but declining to 4.44% in December 2023. The return on equity (ROE) stood at 0.88%, while the return on capital employed (ROCE) was recorded at 4.73%. The cash conversion cycle (CCC) has lengthened significantly to 332.82 days, indicating potential inefficiencies in working capital management. These profitability and efficiency metrics suggest that while the company has periods of strong performance, its overall ability to sustain profitability remains inconsistent, posing challenges for long-term financial health.
Balance Sheet Strength and Financial Ratios
Concord Drugs Ltd’s balance sheet reveals a total borrowing figure of ₹14.89 Cr against reserves of ₹24.42 Cr. The company’s debt-to-equity ratio stands at 0.50, indicating a moderate level of leverage. The interest coverage ratio (ICR) is reported at 2.05x, suggesting adequate ability to cover interest expenses, though this is lower than typical industry standards. The price-to-book value (P/BV) ratio of 0.91x reflects that the stock may be undervalued compared to its book value, which stands at ₹34.11 per share. The current ratio is reported at 1.56, indicating a reasonable liquidity position. However, the decline in net profit margin to 0.74% in March 2025 from 1.05% in March 2024 highlights potential profitability pressures that could affect the company’s balance sheet strength moving forward.
Shareholding Pattern and Investor Confidence
As of September 2025, Concord Drugs Ltd has a diverse shareholding structure, with promoters holding 54.39% of the company, while public shareholders comprise 45.61%. This indicates a stable control by promoters, which can enhance investor confidence. The number of shareholders has increased to 4,718, marking a significant rise from 3,321 in December 2022. This growth in the shareholder base suggests increasing interest in the company, despite its recent profitability challenges. The fluctuation in promoter shareholding from 49% in December 2022 to 54.39% by September 2025 reflects a consolidation of control, which may be perceived positively by investors. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could signal a lack of institutional confidence in the company’s growth prospects.
Outlook, Risks, and Final Insight
The outlook for Concord Drugs Ltd hinges on its ability to stabilize revenue and improve profitability metrics. While the company has demonstrated resilience with occasional revenue rebounds, persistent fluctuations in sales and profitability pose risks to sustainable growth. Key strengths include a solid promoter holding that can drive strategic decisions and a relatively favorable debt position. However, risks such as increased competition, operational inefficiencies reflected in the cash conversion cycle, and declining profitability margins could hinder future performance. In scenarios where the company can effectively streamline its operations and enhance sales consistency, it could potentially regain investor confidence and improve its market standing. Conversely, failure to address these operational challenges may lead to continued volatility in financial performance and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 185/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,651 Cr. | 336 | 479/192 | 76.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.4 Cr. | 42.4 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.1 Cr. | 54.0 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,107.97 Cr | 1,115.87 | 54.49 | 201.93 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.72 | 13.53 | 11.54 | 8.79 | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 | 10.07 |
| Expenses | 12.53 | 12.08 | 10.80 | 7.39 | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 | 9.06 |
| Operating Profit | 1.19 | 1.45 | 0.74 | 1.40 | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 | 1.01 |
| OPM % | 8.67% | 10.72% | 6.41% | 15.93% | 20.73% | 4.44% | 1.31% | 11.50% | 6.67% | 12.26% | 11.68% | 7.03% | 10.03% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.42 | 0.45 | 0.42 | 0.39 | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 | 0.40 |
| Depreciation | 0.53 | 0.38 | 0.31 | 0.38 | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 | 0.34 |
| Profit before tax | 0.24 | 0.62 | 0.01 | 0.63 | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 | 0.27 |
| Tax % | 25.00% | 25.81% | -600.00% | 23.81% | 31.17% | -4.00% | -39.66% | 50.00% | 28.57% | 57.69% | 33.33% | 26.67% | 29.63% |
| Net Profit | 0.18 | 0.45 | 0.07 | 0.49 | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 |
| EPS in Rs | 0.21 | 0.51 | 0.08 | 0.53 | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 |
Last Updated: December 27, 2025, 11:33 am
Below is a detailed analysis of the quarterly data for Concord Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 10.07 Cr.. The value appears to be declining and may need further review. It has decreased from 13.38 Cr. (Jun 2025) to 10.07 Cr., marking a decrease of 3.31 Cr..
- For Expenses, as of Sep 2025, the value is 9.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.44 Cr. (Jun 2025) to 9.06 Cr., marking a decrease of 3.38 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.94 Cr. (Jun 2025) to 1.01 Cr., marking an increase of 0.07 Cr..
- For OPM %, as of Sep 2025, the value is 10.03%. The value appears strong and on an upward trend. It has increased from 7.03% (Jun 2025) to 10.03%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.40 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.42 Cr. (Jun 2025) to 0.40 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.34 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.37 Cr. (Jun 2025) to 0.34 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Jun 2025) to 0.27 Cr., marking an increase of 0.12 Cr..
- For Tax %, as of Sep 2025, the value is 29.63%. The value appears to be increasing, which may not be favorable. It has increased from 26.67% (Jun 2025) to 29.63%, marking an increase of 2.96%.
- For Net Profit, as of Sep 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.08 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.19. The value appears strong and on an upward trend. It has increased from 0.11 (Jun 2025) to 0.19, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 42.18 |
| Expenses | 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 37.98 |
| Operating Profit | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.20 |
| OPM % | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 9.96% |
| Other Income | 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.78 |
| Depreciation | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.45 |
| Profit before tax | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 0.97 |
| Tax % | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | |
| Net Profit | 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 0.53 |
| EPS in Rs | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.88% | 150.00% | -90.86% | 100.00% | 28.12% | -19.51% | 893.94% | -51.52% | -44.03% | -52.81% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 44.12% | -240.86% | 190.86% | -71.88% | -47.64% | 913.45% | -945.46% | 7.50% | -8.78% | 24.24% |
Concord Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -2% |
| 3 Years: | -43% |
| TTM: | 880% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 29% |
| 3 Years: | 26% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 10, 2025, 4:06 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 10.00 |
| Reserves | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 24.42 |
| Borrowings | 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 14.89 |
| Other Liabilities | 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 12.87 |
| Total Liabilities | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
| Fixed Assets | 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.48 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.05 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| Other Assets | 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 47.03 |
| Total Assets | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
Below is a detailed analysis of the balance sheet data for Concord Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 24.42 Cr.. The value appears strong and on an upward trend. It has increased from 24.11 Cr. (Mar 2025) to 24.42 Cr., marking an increase of 0.31 Cr..
- For Borrowings, as of Sep 2025, the value is 14.89 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 16.91 Cr. (Mar 2025) to 14.89 Cr., marking a decrease of 2.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 12.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.56 Cr. (Mar 2025) to 12.87 Cr., marking an increase of 5.31 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.48 Cr.. The value appears to be declining and may need further review. It has decreased from 12.17 Cr. (Mar 2025) to 11.48 Cr., marking a decrease of 0.69 Cr..
- For CWIP, as of Sep 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.05 Cr..
- For Investments, as of Sep 2025, the value is 1.62 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.62 Cr..
- For Other Assets, as of Sep 2025, the value is 47.03 Cr.. The value appears strong and on an upward trend. It has increased from 42.79 Cr. (Mar 2025) to 47.03 Cr., marking an increase of 4.24 Cr..
- For Total Assets, as of Sep 2025, the value is 62.18 Cr.. The value appears strong and on an upward trend. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
Notably, the Reserves (24.42 Cr.) exceed the Borrowings (14.89 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.08 | -14.24 | -11.69 | -9.93 | -8.84 | -6.18 | -6.23 | -9.75 | -10.84 | -11.29 | -11.25 | -13.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 |
| Inventory Days | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 |
| Days Payable | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 |
| Cash Conversion Cycle | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 |
| Working Capital Days | 55.48 | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 134.22 |
| ROCE % | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Cash EPS (Rs.) | 1.77 | 2.03 | 2.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Revenue From Operations / Share (Rs.) | 45.24 | 44.92 | 55.91 |
| PBDIT / Share (Rs.) | 4.15 | 4.05 | 4.92 |
| PBIT / Share (Rs.) | 2.72 | 2.50 | 3.17 |
| PBT / Share (Rs.) | 0.69 | 0.62 | 1.34 |
| Net Profit / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| NP After MI And SOA / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| PBDIT Margin (%) | 9.16 | 9.01 | 8.79 |
| PBIT Margin (%) | 6.00 | 5.55 | 5.67 |
| PBT Margin (%) | 1.52 | 1.40 | 2.39 |
| Net Profit Margin (%) | 0.74 | 1.05 | 1.89 |
| NP After MI And SOA Margin (%) | 0.74 | 1.05 | 1.89 |
| Return on Networth / Equity (%) | 0.98 | 1.39 | 3.10 |
| Return on Capital Employeed (%) | 6.97 | 6.66 | 8.07 |
| Return On Assets (%) | 0.51 | 0.80 | 1.69 |
| Long Term Debt / Equity (X) | 0.03 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.50 | 0.49 | 0.50 |
| Asset Turnover Ratio (%) | 0.73 | 0.76 | 0.00 |
| Current Ratio (X) | 1.56 | 2.09 | 2.01 |
| Quick Ratio (X) | 0.59 | 1.02 | 1.08 |
| Inventory Turnover Ratio (X) | 1.88 | 2.09 | 0.00 |
| Interest Coverage Ratio (X) | 2.05 | 2.17 | 2.68 |
| Interest Coverage Ratio (Post Tax) (X) | 1.17 | 1.25 | 1.58 |
| Enterprise Value (Cr.) | 48.05 | 51.59 | 41.61 |
| EV / Net Operating Revenue (X) | 1.06 | 1.15 | 0.79 |
| EV / EBITDA (X) | 11.58 | 12.73 | 9.08 |
| MarketCap / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| Price / BV (X) | 0.91 | 1.04 | 0.80 |
| Price / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 |
After reviewing the key financial ratios for Concord Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.77. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.77, marking a decrease of 0.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 45.24. It has increased from 44.92 (Mar 24) to 45.24, marking an increase of 0.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.15. This value is within the healthy range. It has increased from 4.05 (Mar 24) to 4.15, marking an increase of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.72, marking an increase of 0.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 0.69, marking an increase of 0.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For PBDIT Margin (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 10. It has increased from 9.01 (Mar 24) to 9.16, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 5.55 (Mar 24) to 6.00, marking an increase of 0.45.
- For PBT Margin (%), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 10. It has increased from 1.40 (Mar 24) to 1.52, marking an increase of 0.12.
- For Net Profit Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 8. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 15. It has decreased from 1.39 (Mar 24) to 0.98, marking a decrease of 0.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.97. This value is below the healthy minimum of 10. It has increased from 6.66 (Mar 24) to 6.97, marking an increase of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.51, marking a decrease of 0.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 0.50, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.76 (Mar 24) to 0.73, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.56, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.59, marking a decrease of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 4. It has decreased from 2.09 (Mar 24) to 1.88, marking a decrease of 0.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.05. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 2.05, marking a decrease of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has decreased from 1.25 (Mar 24) to 1.17, marking a decrease of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 48.05. It has decreased from 51.59 (Mar 24) to 48.05, marking a decrease of 3.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.15 (Mar 24) to 1.06, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.58. This value is within the healthy range. It has decreased from 12.73 (Mar 24) to 11.58, marking a decrease of 1.15.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.91, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Drugs Ltd:
- Net Profit Margin: 0.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.97% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 150 (Industry average Stock P/E: 54.49)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.5
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.249, R R District Telangana 501511 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Nagi Reddy | Chairman & Managing Director |
| Mr. S Manoj Kumar Reddy | Whole Time Director |
| Mr. S Koni Reddy | WholeTime Director & CFO |
| Mr. K Ramachandra Reddy | Independent Director |
| Ms. Sumeela Kasu | Independent Director |
| Mr. S Nagavenkata Hareesh | Independent Director |
FAQ
What is the intrinsic value of Concord Drugs Ltd?
Concord Drugs Ltd's intrinsic value (as of 09 February 2026) is ₹28.95 which is 63.72% lower the current market price of ₹79.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹79.8 Cr. market cap, FY2025-2026 high/low of ₹92.5/26.1, reserves of ₹24.42 Cr, and liabilities of ₹62.18 Cr.
What is the Market Cap of Concord Drugs Ltd?
The Market Cap of Concord Drugs Ltd is 79.8 Cr..
What is the current Stock Price of Concord Drugs Ltd as on 09 February 2026?
The current stock price of Concord Drugs Ltd as on 09 February 2026 is ₹79.8.
What is the High / Low of Concord Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Drugs Ltd stocks is ₹92.5/26.1.
What is the Stock P/E of Concord Drugs Ltd?
The Stock P/E of Concord Drugs Ltd is 150.
What is the Book Value of Concord Drugs Ltd?
The Book Value of Concord Drugs Ltd is 34.4.
What is the Dividend Yield of Concord Drugs Ltd?
The Dividend Yield of Concord Drugs Ltd is 0.00 %.
What is the ROCE of Concord Drugs Ltd?
The ROCE of Concord Drugs Ltd is 4.73 %.
What is the ROE of Concord Drugs Ltd?
The ROE of Concord Drugs Ltd is 0.88 %.
What is the Face Value of Concord Drugs Ltd?
The Face Value of Concord Drugs Ltd is 10.0.